In a final analysis of the Peter Mac sponsored Azacitidine/Eltrombopag study, haematologist and research fellow, Dr Michael Dickinson, targets myelodysplastic syndromes and gives us a lay summary of the purpose of the trial.  Myelodysplastic syndromes are a group of conditions that lead to ineffective production of normal blood cells by the bone marrow. Patients present … Continued